{
    "organizations": [],
    "uuid": "e58d33deeaa3226cc0c6f1ac703c91f12e579bf1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fda-issues-alert-on-use-of-keytrud/brief-fda-issues-alert-on-use-of-keytruda-tecentriq-for-patients-with-urothelial-cancer-have-low-expression-of-pd-l1-idUSFWN1SP0UY",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Issues Alert On Use Of Keytruda/Tecentriq For Patients With Urothelial Cancer, Have Low Expression Of PD-L1",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 18 (Reuters) - FDA:\n* U.S. FDA - ISSUES ALERT ABOUT DECREASED SURVIVAL ASSOCIATED WITH THE USE OF KEYTRUDA (PEMBROLIZUMAB) OR TECENTRIQ (ATEZOLIZUMAB)\n* U.S. FDA SAYS THERE WAS NO CHANGE IN THE ADVERSE EVENT PROFILE OF KEYTRUDA OR TECENTRIQ\n* FDA - MERCK, GENENTECH HAVE STOPPED ENROLLING PATIENTS WHOSE TUMORS HAVE PD-L1 LOW STATUS TO KEYTRUDA/TECENTRIQ MONOTHERAPY ARMS PER DMCSâ€™ RECOMMENDATIONS\n* U.S. FDA SAYS MONOTHERAPY ARMS REMAIN OPEN ONLY TO PATIENTS WHOSE TUMORS HAVE PD-L1 HIGH STATUS\n* U.S. FDA - COMBINATION ARMS AND THE CHEMOTHERAPY ARMS OF BOTH STUDIES ALSO REMAIN OPEN\n* FDA - ISSUED ALERT ON KEYTRUDA/TECENTRIQ AS MONOTHERAPY FOR PATIENTS WITH UROTHELIAL CANCER WHO HAVE NOT RECEIVED PRIOR THERAPY, HAVE LOW EXPRESSION OF PD-L1 Source text : ( bit.ly/2k9egH8 ) Further company coverage:\n ",
    "published": "2018-05-19T00:21:00.000+03:00",
    "crawled": "2018-05-19T15:20:21.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "fda",
        "fda",
        "issue",
        "alert",
        "decreased",
        "survival",
        "associated",
        "use",
        "keytruda",
        "pembrolizumab",
        "tecentriq",
        "atezolizumab",
        "fda",
        "say",
        "change",
        "adverse",
        "event",
        "profile",
        "keytruda",
        "tecentriq",
        "fda",
        "merck",
        "genentech",
        "stopped",
        "enrolling",
        "patient",
        "whose",
        "tumor",
        "low",
        "status",
        "monotherapy",
        "arm",
        "per",
        "dmcs",
        "recommendation",
        "fda",
        "say",
        "monotherapy",
        "arm",
        "remain",
        "open",
        "patient",
        "whose",
        "tumor",
        "high",
        "status",
        "fda",
        "combination",
        "arm",
        "chemotherapy",
        "arm",
        "study",
        "also",
        "remain",
        "open",
        "fda",
        "issued",
        "alert",
        "monotherapy",
        "patient",
        "urothelial",
        "cancer",
        "received",
        "prior",
        "therapy",
        "low",
        "expression",
        "source",
        "text",
        "company",
        "coverage"
    ]
}